Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
104.26
+2.61 (2.57%)
At close: Jun 24, 2025, 4:00 PM
104.00
-0.26 (-0.25%)
After-hours: Jun 24, 2025, 7:58 PM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Axsome Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $170.5, which forecasts a 63.53% increase in the stock price over the next year. The lowest target is $105 and the highest is $216.
Price Target: $170.5 (+63.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 7 | 7 | 7 |
| Buy | 7 | 8 | 8 | 8 | 8 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $193 → $186 | Buy | Maintains | $193 → $186 | +78.40% | Jun 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $180 | Strong Buy | Reiterates | $180 | +72.65% | Jun 10, 2025 |
| Needham | Needham | Strong Buy Maintains $153 → $150 | Strong Buy | Maintains | $153 → $150 | +43.87% | Jun 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $185 | Buy | Initiates | $185 | +77.44% | Jun 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $180 | Strong Buy | Reiterates | $180 | +72.65% | May 22, 2025 |
Financial Forecast
Revenue This Year
628.06M
from 385.69M
Increased by 62.84%
Revenue Next Year
1.01B
from 628.06M
Increased by 60.02%
EPS This Year
-3.57
from -5.99
EPS Next Year
1.72
from -3.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 696.9M | 1.2B | 1.9B | ||
| Avg | 628.1M | 1.0B | 1.5B | ||
| Low | 569.6M | 806.5M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 80.7% | 85.5% | 92.7% | ||
| Avg | 62.8% | 60.0% | 52.8% | ||
| Low | 47.7% | 28.4% | 14.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.94 | 5.26 | 16.09 | ||
| Avg | -3.57 | 1.72 | 9.60 | ||
| Low | -4.36 | -2.49 | 2.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 836.6% | ||
| Avg | - | - | 459.0% | ||
| Low | - | - | 31.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.